Singapore markets open in 7 hours 29 minutes
  • Straits Times Index

    -3.28 (-0.10%)
  • S&P 500

    +24.74 (+0.54%)
  • Dow

    +87.91 (+0.25%)
  • Nasdaq

    +136.01 (+0.90%)

    +2,771.96 (+4.58%)
  • CMC Crypto 200

    +1,270.72 (+523.62%)
  • FTSE 100

    +18.27 (+0.25%)
  • Gold

    +10.80 (+0.60%)
  • Crude Oil

    +0.37 (+0.44%)
  • 10-Yr Bond

    -0.0220 (-1.33%)
  • Nikkei

    -204.44 (-0.71%)
  • Hang Seng

    +5.10 (+0.02%)
  • FTSE Bursa Malaysia

    -0.14 (-0.01%)
  • Jakarta Composite Index

    -18.04 (-0.27%)
  • PSE Index

    -78.07 (-1.07%)

Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, taking place on September 13-15, 2021.

Details are as follows:

Conference: Morgan Stanley 19th Annual Global Healthcare Conference
Fireside Chat: Friday, September 10, 2021, 10:15am EST; live and available for replay
Webcast Link

Conference: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021; available for replay
Webcast Link

The presentation webcasts can be accessed by visiting the Investors & Media section of the company’s website at The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Ikena Oncology

Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing multiple programs that target tumor markers as well as programs targeting the tumor microenvironment. The Company’s lead program, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway, a pathway that can drive formation and increase survival of tumors and also drives development of resistance to multiple existing therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and several programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit or follow us on Twitter and LinkedIn.

Media Contact:
Gwen Schanker
LifeSci Communications

Investor Contact:
Rebecca Cohen
Ikena Oncology

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting